UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Jan

    21

    Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

    Jan

    19

    UCB to acquire Zogenix

    Jan

    18

    Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study